Endocrinological Study of the Dopaminergic Regulation of Prolactin Release in Metastatic Breast Cancer
| Autor: | Giorgio Confalonieri, Gabriele Fumagalli, Paolo Lissoni, Cecilia Moro, Gabriele Tancini, Sandro Barni, L. Giani, Franco Rovelli, Antonio Ardizzoia, Fabio Malugani, Mario Mandalà |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
endocrine system Cancer Research medicine.medical_specialty Metoclopramide Dopamine medicine.medical_treatment Breast Neoplasms Endogeny 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Humans Endocrine system Aged business.industry Growth factor Dopaminergic General Medicine Middle Aged medicine.disease Metastatic breast cancer Prolactin Endocrinology Oncology 030220 oncology & carcinogenesis Dopamine Antagonists Female business hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Tumori Journal. 85:494-497 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089169908500613 |
| Popis: | Aims and Background Prolactin (PRL) may be a growth factor for breast cancer. Abnormally high levels of PRL have been proven to be associated with a poor prognosis in metastatic breast cancer. However, most studies have been limited to the evaluation of basal levels of PRL rather than its response to the classical endocrine dynamic tests. This study was performed to analyse the dynamic secretion of PRL under stimulatory and inhibitory tests in metastatic breast cancer. Methods The study included 10 untreated metastatic breast cancer women, who were evaluated after the classical stimulatory and inhibitory tests for PRL secretion with the antidopaminergic agent Metoclopramide (10 mg iv as a bolus) and with L-dopa, respectively. Serum levels of PRL were measured by RIA before and at subsequent intervals after drug administration. PRL levels were considered to be elevated when they were higher than 25 ng/ml. Results Abnormally high basal levels of PRL were seen in 6/10 patients. L-dopa was unable to inhibit PRL secretion, whose mean concentrations paradoxically significantly increased in response to L-dopa, with values comparable to those observed after the classical stimulatory test with metoclopramide. Conclusions This study confirm the existence of hyperprolactinemia associated with metastatic breast cancer. In addition, by showing a paradoxical rise of PRL in response to L-dopa, which inhibits PRL secretion in physiological conditions, this study would suggest that breast cancer-related hyperprolactinemia may depend at least in part on endogenous disease-related neuroendocrine alterations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|